SAT-175 Trial in Progress Interim Report: A Phase II Clinical Trial Using Single Agent Cabozantinib in Advanced Adrenocortical Carcinoma

BACKGROUND: Adrenocortical carcinoma (ACC) in an aggressive malignancy with suboptimal response to frontline chemotherapy and without established second line treatment. cMET activation is associated with ACC resistance to chemotherapy. Cabozantinib is a multi-kinase inhibitor that targets the VEGFR,...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Endocr Soc
Prif Awduron: Bedrose, Sara Shokry Daniel, Altameemi, Lina, Daher, Marilyne, De Rosa, Gina Tamsen, Varghese, Jeena Mary, Jimenez, Camilo, Campbell, Matthew, Habra, Mouhammed Amir
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2020
Pynciau:
Adrenal
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7209711/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvaa046.508
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg